Zydus Lifesciences Gets Clean USFDA Report for Ahmedabad Unit

07 Nov 2025 CW Team

The Pre-Approval Inspection (PAI) was conducted between 11 and 14 August 2025 and concluded without any observations. Following the inspection, the USFDA issued an Establishment Inspection Report (EIR), classifying the site as “No Action Indicated” (NAI) — effectively closing the inspection.

Zydus stated that the outcome reaffirms its strong compliance standards and enhances its regulatory track record, paving the way for future product approvals from the facility. The disclosure was made in line with Regulation 30 of SEBI’s Listing Obligations and Disclosure Requirements (LODR).

The company also announced that its Board of Directors will meet on 6 November to consider a proposal to raise up to Rs 50 billion through the issue of eligible securities. The fundraising options may include a qualified institutional placement (QIP), rights issue, preferential allotment, or private placement.

Additionally, the board will consider initiating a postal ballot process to seek shareholder approval for the proposed fundraising. The company is also scheduled to announce its July–September quarter results on the same day.

In the first quarter of FY26, Zydus reported a 3.3 per cent rise in net profit to Rs 14.67 billion, supported by a foreign exchange gain of Rs 570 million. Revenue for the quarter grew 6 per cent year-on-year to Rs 65.74 billion, while EBITDA remained flat at Rs 20.89 billion. Profit margins stood at 31.8 per cent, compared with 33.6 per cent a year earlier.

The clean USFDA report is expected to further strengthen Zydus Lifesciences’ regulatory credibility and growth prospects in the US pharmaceutical market.

Zydus Lifesciences Ltd has received a clean report from the US Food and Drug Administration (USFDA) for its manufacturing facility at SEZ-II in Ahmedabad, the company informed in a stock exchange filing on Wednesday, 5 November. The Pre-Approval Inspection (PAI) was conducted between 11 and 14 August 2025 and concluded without any observations. Following the inspection, the USFDA issued an Establishment Inspection Report (EIR), classifying the site as “No Action Indicated” (NAI) — effectively closing the inspection. Zydus stated that the outcome reaffirms its strong compliance standards and enhances its regulatory track record, paving the way for future product approvals from the facility. The disclosure was made in line with Regulation 30 of SEBI’s Listing Obligations and Disclosure Requirements (LODR). The company also announced that its Board of Directors will meet on 6 November to consider a proposal to raise up to Rs 50 billion through the issue of eligible securities. The fundraising options may include a qualified institutional placement (QIP), rights issue, preferential allotment, or private placement. Additionally, the board will consider initiating a postal ballot process to seek shareholder approval for the proposed fundraising. The company is also scheduled to announce its July–September quarter results on the same day. In the first quarter of FY26, Zydus reported a 3.3 per cent rise in net profit to Rs 14.67 billion, supported by a foreign exchange gain of Rs 570 million. Revenue for the quarter grew 6 per cent year-on-year to Rs 65.74 billion, while EBITDA remained flat at Rs 20.89 billion. Profit margins stood at 31.8 per cent, compared with 33.6 per cent a year earlier. The clean USFDA report is expected to further strengthen Zydus Lifesciences’ regulatory credibility and growth prospects in the US pharmaceutical market.

Infrastructure Transport

06 Feb 2026

Lucknow Metro East-West Corridor Consultancy Contract Awarded

The Uttar Pradesh Metro Rail Corporation has awarded the first construction-related consultancy contract for the Lucknow Metro East West Corridor to a joint venture of AYESA Ingenieria Arquitectura SAU and AYESA India Pvt Ltd. The firm was declared the lowest bidder for the Detailed Design Consultant contract for Lucknow Metro Line-2 under Phase 1B and the contract was recommended following the financial bid. The contract is valued at Rs 159.0 million (mn), covering design services for the corridor. Lucknow Metro Line-2 envisages the construction of an 11.165 kilometre corridor connecting Cha..

Infrastructure Urban

06 Feb 2026

Div Com Kashmir Urges Fast Tracking Of Jhelum Water Transport Project

The Divisional Commissioner of Kashmir has called for the fast-tracking of the Jhelum water transport project, urging district administrations and relevant agencies to accelerate planning and clearances. In a meeting convened at the divisional headquarters, the commissioner instructed officials from irrigation, public health engineering and municipal departments to prioritise the project and coordinate survey and design work. The directive emphasised removal of administrative bottlenecks and close monitoring to ensure timely mobilisation of resources and contractors. Officials were told to in..

Infrastructure Urban

06 Feb 2026

Interarch Reports Strong Q3 And Nine Month Results

Interarch Building Solutions Limited reported unaudited results for the third quarter and nine months ended 31 December 2025, recording strong revenue growth driven by execution and a robust order book. Net revenue for the third quarter rose by 43.7 per cent to Rs 5.225 billion (bn), compared with Rs 3.636 bn a year earlier, reflecting heightened demand in pre-engineered building projects. The company’s total order book as at 31 January 2026 stood at Rs 16.85 bn, supporting near-term visibility. EBITDA excluding other income for the quarter increased by 43.2 per cent to Rs 503 million (mn),..